MedDataX Logo

RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial

NCT ID: NCT01127542

Last Updated: 2011-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The majority of patients with CLL are diagnosed with early stage disease (Binet stage A or Rai stage 0/I). Standard management of such patients is observation, and with median age at diagnosis of 72 and median time to progression of \>5-10 years, many will never require treatment. In contrast, a proportion of patients have more aggressive disease, and over the last decade, a number of molecular factors have been identified that may be used to identify patients with poor prognosis disease . Each is associated with shortened time to treatment (typically less than 3 years in patients with 2 of more factors), reduced survival, with in the case of p53/ATM inactivation, resistance to treatment. Whether it is possible to improve the outcome of patients with CLL and adverse prognostic factors by early intervention with treatment is unknown. Several trials in the 1980's demonstrated that treatment of stage A CLL with conventional chemotherapy (chlorambucil) did not alter the natural history of the disease, although none of these studies stratified patients according to risk. The choice of alternative potential therapeutic agents is limited; they should be effective in patients with adverse prognostic factors, have acceptable toxicity, be able to overcome the drug resistance associated with p53/ATM inactivation and ideally be orally administered. Two recent phase II trials have demonstrated that Lenalidomide is effective in the treatment of relapsed/refractory disease. Importantly, both studies included a high proportion of patients with adverse prognostic factors including p53 inactivation. The principle objective of this study is to investigate the efficacy of Lenalidomide in achieving disease response (complete remission and clearance of minimal residual disease) in patients with poor risk early stage disease, together with assessment of safety and tolerability.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukaemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lenalidomide for early stage poor prognosis CLL

Group Type EXPERIMENTAL

Lenalidomide

Intervention Type DRUG

Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lenalidomide

Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Revlimid CC-5013

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Binet stage A CLL
* 2 or more risk factors:
* Unmutated IgVH locus (≥98% homology to germline sequence)
* CD38 expression (\>7%)
* Deletion of chromosome 11q22 (\>20% by FISH)
* Deletion of chromosome 17p13 (\>10% by FISH)
* Over 18 years old
* Capable to provide written informed consent
* ECOG performance status \< 2
* Life expectancy \> 2 years
* Must agree to not share lenalidomide with someone else
* Must agree not to donate blood whilst taking the study drug and for one week after discontinuation of treatment.
* Female subjects of childbearing potential and all male subjects must agree to comply with the stipulations of the pregnancy prevention plan.

Exclusion Criteria

* Current or recent (within the last 1 month) participation in another clinical trial investigating the action of an investigational medicinal product for the treatment of CLL
* Pregnant or lactating
* Known positivity for human immunodeficiency virus (HIV) types 1 or 2
* Prior history of malignancies, other than CLL, unless the subject was treated with curative intent and has been free of the disease for ≥3 years. Exceptions include the following:
* Basal cell carcinoma of the skin
* Squamous cell carcinoma of the skin
* Carcinoma in situ of the cervix
* Carcinoma in situ of the breast
* Significantly abnormal renal or hepatic function (creatinine clearance \< 60ml/min, serum aspartate aminotransferase (AST) \> 3 x upper limit of normal (ULN), serum bilirubin \> 34μmol/l)
* Laboratory tumour lysis syndrome according to the Cairo-Bishop classification. Subjects may be enrolled when these abnormalities have been corrected.
* Peripheral neuropathy (grade ≥ 2)
* Previous treatment for CLL
* Previous treatment with Thalidomide or immunomodulatory derivative drugs (including Lenalidomide)
* Treatment with corticosteroids (for CLL or other indications) \< 28 days from study entry
* Evidence of Richter's transformation
* Unsupported absolute neutrophil count \< 1x109/l or platelet count \< 50x10\*9/l not due to CLL
* Active autoimmune haemolytic anaemia or thrombocytopenia
* Any other medical or psychological condition that in the view of the investigator would be likely to impact compliance with the protocol or interfere with trial treatment.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Celgene Corporation

INDUSTRY

Sponsor Role collaborator

Leukemia Research Fund

OTHER

Sponsor Role collaborator

The Christie NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Christie NHS Foundation Trust

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Adrian Bloor

Role: PRINCIPAL_INVESTIGATOR

The Christie NHS Foundation Trust

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Royal Bournemouth Hospital

Bournemouth, Dorset, United Kingdom

Site Status

Heart of England NHS Foundation Trust

Birmingham, , United Kingdom

Site Status

Addenbrooke's Hospital

Cambridge, , United Kingdom

Site Status

University Hospital of Wales

Cardiff, , United Kingdom

Site Status

St James's University Hospital

Leeds, , United Kingdom

Site Status

The Royal Liverpool and Broadgreen University Hospital

Liverpool, , United Kingdom

Site Status

King's College Hospital

London, , United Kingdom

Site Status

The Christie NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Mid Yorkshire Hospitals NHS Trust

Wakefield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-011078-14

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

ISRCTN

Identifier Type: REGISTRY

Identifier Source: secondary_id

09_DOG06_99

Identifier Type: -

Identifier Source: org_study_id